Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Daiwa Health Development Launches Plasmanex1
February 4, 2009
1 Min Read
LOS ANGELES—Plasmanex1™, a dietary supplement with the active ingredient Bacillopeptidase F Proprietary Blend (BFPB), a natural soy enzyme extracted by using a patented fermentation production process and shown to support healthy blood circulation, was introduced to the health practitioner marketplace by Daiwa Health Development.
Plasmanex1 has three primary functions, confirmed through several studies, including balancing blood flow through PAI-1 and t-PA, retarding thrombosis in abnormal coagulation states and decreasing blood viscosity through reduction of fibrinogen.
Recent studies revealed Plasmanex1 normalized the coagulation factors at various rates. Coagulation levels did not drop below normal levels with use of Plasmanex1, yet by reducing production of pro-coagulant factors and reduction of unwanted wasted overuse of plasmin, it may be a desirable modulation of coagulation status.
As a dietary supplement, the recommended dosage for Plasmanex1™ is one or two capsules before bedtime, or one in the morning and one at night. One capsule a day is recommended when Plasmanex1™ is used chronically and a possible history of bleeding exists.
You May Also Like